Hyperphosphatemia of chronic kidney disease  by Hruska, Keith A. et al.
Hyperphosphatemia of chronic kidney disease
Keith A. Hruska1,2, Suresh Mathew1, Richard Lund3, Ping Qiu4 and Raymond Pratt4
1Department of Pediatrics, Renal Division, Washington University, St Louis, Missouri, USA; 2Department of Medicine, Renal Division,
Washington University, St Louis, Missouri, USA; 3Department of Medicine, Creighton University, Omaha, Nebraska, USA and
4Shire Pharmaceuticals, Wayne, Pennsylvania, USA
Observational studies have determined hyperphosphatemia
to be a cardiovascular risk factor in chronic kidney disease.
Mechanistic studies have elucidated that hyperphosphatemia
is a direct stimulus to vascular calcification, which is one
cause of morbid cardiovascular events contributing to the
excess mortality of chronic kidney disease. This review
describes the pathobiology of hyperphosphatemia that
develops as a consequence of positive phosphate balance in
chronic kidney disease and the mechanisms by which
hyperphosphatemia acts on neointimal vascular cells that are
stimulated to mineralize in chronic kidney disease. The
characterization of hyperphosphatemia of chronic kidney
disease as a distinct syndrome in clinical medicine with
unique disordered skeletal remodeling, heterotopic
mineralization and cardiovascular morbidity is presented.
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Hyperphosphatemia is associated with significant pathophy-
siology in chronic kidney disease (CKD). This pathophysio-
logy contributes to the high rates of mortality observed in
CKD.1 Approximately 11–15% of Americans have CKD,2–4
and their risk of death due to a cardiovascular event-related
cause is higher than their risk of surviving and needing renal
replacement therapy for end-stage kidney disease (ESKD).1,2,4
The mortality rates of patients surviving CKD and receiving
hemodialysis are extremely high such that a 30-year-old
patient with ESKD has a life expectancy similar to that of a 90
year old with normal renal function.2 The mechanisms of this
excess risk of cardiovascular disease are not completely
understood. The well-characterized risks of cardiovascular
disease in the general population do not explain the increased
risk in CKD.1,3 Observational studies suggest that the well-
known propensity of ESKD patients to develop heterotopic
mineralization of soft tissues, including the vasculature, is an
important component of the cardiovascular risks of ESKD.5,6
Furthermore, several observational studies demonstrate that
hyperphosphatemia is an independent cardiovascular risk
factor in CKD.7–9 Hyperphosphatemia has been linked to
vascular calcification.5,10,11
PATHOGENESIS
To consider the pathogenesis of hyperphosphatemia in CKD,
it is useful to review the mechanisms of phosphate home-
ostasis (Figure 1). We ingest approximately 1000–1200 mg of
phosphorus in the average American diet of 2007. Of this, a
net weight of about 800 mg is absorbed into the exchangeable
phosphorus pool. This pool consists of intracellular phos-
phorus (70%), the skeletal mineralization front (29%), and
the serum phosphorus (o1%). Exit from the exchangeable
pool occurs through skeletal deposition, renal excretion, and
intestinal secretion (Figure 1). Exit from the exchangeable
pool into the skeleton is matched by entry from the skeleton
into the pool in adulthood, and therefore, we do not
normally think of the skeleton as a key contributor to the
level of phosphorus concentration in the pool, but in CKD, as
will be shown in the sections below, it is very important.
Regulation of phosphorus excretion by the kidney is the key
mechanism of maintaining phosphate balance in normal
day-to-day life. Kidney injury impairs the ability of mammals
to maintain phosphorus balance, and in human CKD,
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phosphorus homeostasis is lost and positive phosphate
balance occurs in the later stages (4 and 5) of kidney
diseases.12,13 Loss of phosphorus homeostasis due to excre-
tion failure in CKD results in hyperphosphatemia14 due to
positive balance increasing the concentration in the
exchangeable phosphorus pool, often when the pool size is
reduced as in the adynamic bone disorder (ABD) (Figure 2).
Surprisingly, and not generally adequately considered, the
skeleton contributes to hyperphosphatemia in CKD and
ESKD through the effects of disordered bone remodeling.
There are multiple skeletal remodeling disorders in CKD that
have been discussed in the sections below, but all of them are
associated with excess bone resorption compared with bone
formation. Thereby, they contribute to hyperphosphatemia
and effectively block the skeleton from exerting its normal
reservoir function when positive phosphate balance occurs.
The normal function of the skeleton as a reservoir when
phosphate balance is positive is seen in several syndromes
of hyperphosphatemia in mammalian pathophysiology
(Table 1). All of these, except immobilization and CKD,
are associated with increased skeletal mass and mineraliza-
tion due to phosphorus deposition into the skeletal
storage reservoir (see section ‘Other Hyperphosphatemic
Syndromes’). In CKD, there is a complex set of losses and
adaptations in skeletal function that produce bone disorders
that complicate the state (see section ‘Renal Osteodystro-
phy’). Recent discoveries characterize all forms of skeletal
function disorder in CKD as having excess bone resorption
rates compared with bone formation rates (see section
‘Osteoporosis in CKD’). Therefore, the skeleton is contributing
to hyperphosphatemia in CKD, and the reservoir function of
the skeleton that is supposed to act in the presence of positive
phosphorus balance is blocked. The outcome of this change
in physiology to a new pathophysiology requires that a new
phosphate reservoir for the positive balance be established.
This new reservoir is soft tissue organs, including the
vasculature (Figure 2). The problem with establishing
the new reservoirs of phosphate storage is that they produce
disease.
Regulation of phosphate balance during CKD before loss
of balance occurs is complex. Loss of calcitriol production
capacity is an important factor leading to a decrease in Ca
absorption, hypocalcemia, and stimulation of parathyroid
hormone (PTH) secretion (Figure 3). The increase in PTH
levels reduces the fraction of the filtered phosphate load and
maintains phosphate excretion at normal levels despite the
reduction in the filtered load of phosphorus due to
the decrease in glomerular filtration. The decrease in
calcitriol production also represents a decrease in the signal
to the osteocytes and osteoblasts for the production of
fibroblast growth factor 23 (FGF23).15 However, the tendency
for decreased production is overcome by the fact that FGF23
is normally catabolized by glomerular filtration and proximal
tubular degradation. Thus, the protein levels increase in CKD
as the glomerular filtration rate decreases.16,17 This is a
second potent stimulus to phosphorus excretion as kidney
function is diminished. The relative contributions PTH and
FGF23 make to phosphate homeostasis during CKD have not
been determined, but in the absence of either, homeostasis is
lost. A third stimulus for increased phosphate excretion is
Secretion 
(150 mg day–1)
Absorption 
(950 mg day–1)
Excrete feces 
(400 mg day–1)
Excrete urine 
(800 mg day–1)
Phosphorus
pool
Blood <1%
Resorption 
(300 mg day–1)
Resorption 
(300 mg day–1)
Total adult body stores 700 g, 85% in:
1200 mg day–1
1350 mg day–1
Phosphorus balance
Figure 1 | Phosphorus balance in normal physiology. The kidney is the main regulator of human phosphate homeostasis. In adulthood,
exit from the exchangeable phosphorus pool into the skeleton (bone formation) is roughly equal to entry into the exchangeable pool
due to bone resorption. The skeleton is a storage depot for Pi and contains 85% of the total body phosphorus.
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phosphate itself, which also potently inhibits the activity of
the proximal tubular sodium-dependent Pi transport pro-
teins (Na/Pi co-transporters, NaPi2a, and NaPi2c18,19).
The sodium-dependent phosphate transport protein,
NaPi2a (approximately 70% of proximal tubular phosphate
transport), is regulated mainly by endocytic vesicle cycling
in an out of the apical membrane of the epithelial cell.19,20,21
It is directly regulated by Pi concentrations.18,20,21 Low Pi
increases decreases vesicular retrieval from the plasma
membrane, whereas high Pi concentrations stimulate the
same.20 A late effect of Pi concentration is a slight change in
gene transcription of NaPi2a with greater effects on protein
levels, and stimulation of transcription of NaPi2a-associated
proteins (such as diphor-1) by low and inhibition by high
Pi.20,22 Similar experiments have not been performed for the
minor, but very important NaPi2c of the proximal tubule.
NaPi2b of the duodenal enterocyte is a transcriptional target
of the vitamin D receptor and dietary phosphorus,23 but
calcitriol deficiency or hyperphosphatemia in CKD does not
result in decreased intestinal phosphate absorption, because
the decrease in active duodenal transport is compensated by
passive transport through enterocyte paracellular pathways in
the rest of the intestine.
One of the new reservoirs for phosphate deposition
established when excretion is no longer sufficient to maintain
balance, the vasculature (Figure 2), is especially disease
causing. Vascular calcification in CKD is not well tolerated, as
it produces blood vessel stiffness (Figure 4). There are two
forms of vascular calcification prominent in CKD, calcifica-
tion of atherosclerotic neointimal plaques and arterial medial
calcification. CKD markedly stimulates both forms. The
atherosclerotic calcification is especially appreciated in the
coronary arteries, as it is measured by the increasingly
popular imaging techniques for determining coronary artery
calcification.24,25 However, arterial medial calcification is as
clinically important, as it is the likely the most important
factor in vascular stiffness and increased pulse pressure in
CKD.
To study the mechanisms of CKD-stimulated vascular
calcification, we developed a translational animal model. We
started with a model of atherosclerosis that develops cardiac
valvular and atherosclerotic neointimal plaque calcification,
the low-density lipoprotein receptor-deficient mouse
(LDLR/) fed a high-fat diet. To the model we added
ablation-induced kidney failure and demonstrated marked
stimulation of aortic atherosclerotic calcification.26 We
discovered that bone morphogenetic protein-7 (BMP-7)
prevented development of CKD-stimulated vascular calcifi-
cation.26 Furthermore, the high-fat-fed CKD mice exhibited
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Figure 2 | Phosphorus homeostasis is lost in CKD due to failure of excretion. Despite reductions in the fraction of filtered
phosphorus that is reabsorbed, eventually the filtered load becomes insufficient to maintain homeostasis and positive phosphorus
balance ensues. Kidney disease decreases the exchangeable phosphorus pool size by inhibiting bone formation. The skeletal mineralization
fronts at the sites of new bone formation are significant components of the exchangeable phosphorus pool. Positive phosphate
balance is associated with establishment of heterotopic mineralization sites in soft-tissue organs and the vasculature. Exit from the
exchangeable phosphorus pool into the vasculature is portrayed as a bidirectional process because we have been able to demonstrate that
stopping the exit into the vasculature results in diminishment of established vascular calcification levels.
Table 1 | Hyperphosphatemic syndromes
Increased intake
Transcellular shifts from intracellular to extracellular spaces
Excess bone resorption
Decreased renal excretion
Idiopathic hyperparathyroidism
Pseudohypoparathyroidism
FGF23 deficiency
Tumoral calcinosis
Chronic kidney disease
Acromegaly
Artifactual
FGF, fibroblast growth factor.
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hyperphosphatemia that was corrected by BMP-7.27 While
investigating the mechanism of hyperphosphatemia correc-
tion by BMP-7, we found that bone formation was stimulated
correcting the ABD that complicates the kidney failure in
these mice.27 Renal phosphate excretion was not increased,
and we questioned how much of the effect of BMP-7 on
vascular calcification was due to bone formation-induced
correction of hyperphosphatemia. To examine this, we added
phosphate binders to the high-fat diet in an attempt to isolate
hyperphosphatemia correction as a single entity separate
from the other actions of BMP-7. To our surprise, phosphate
binders were very effective in preventing vascular calcifica-
tion. We first used CaCO3,
27 but subsequently have studied
sevelamer carbonate (Figure 5)28 and LaCO3 with similar
results.
The LDLR/, high-fat-fed mouse is characterized by
obesity, hypertension, and insulin resistance that progresses
to diabetes and severe hypercholesterolemia. Thus, the mouse
model is relevant to the human metabolic syndrome, and
the development of kidney disease in obese diabetics. Even
the renal osteodystrophy complicating CKD, the ABD, is the
same as that observed in patients with diabetic nephropathy.
The vascular calcification of the model was discovered by
Towler and Semenkovich.29 They found that osteoblastic
transcriptional activity was present in the aorta, and their
model is the starting point to which we add CKD. At the
beginning, in other words our high-fat-fed, sham-operated
animals expressed BMP-2, BMP-4, Runx2, Msx2, osteocalcin,
and osteopontin in the vasculature, especially the aorta.
This is relevant because several investigators have demon-
strated that the vasculature of patients with CKD/ESKD
expreshyphen-qj;ses osteoblastic markers.30–33 However, our
high-fat-fed, sham-operated animals had a low level of
vascular calcification that was stimulated two- to fourfold by
induction of CKD.26
To further investigate the mechanisms of atherosclerotic
calcification, we developed an in vitro model to study in cell
culture with the strategy of confirming discoveries made
in vitro using our animal model. We began by obtaining
primary cultures of human vascular smooth-muscle cells
(VSMCs) from areas of aortic atherosclerotic plaques, which
were expanded and then exposed to an increase in media
phosphorus concentrations (Figure 6). We demonstrated that
the starting tissue and the primary cultures in regular media
expressed BMP-2, BMP-4, Runx2, Msx2, osteocalcin, and
osteopontin. Thus, it appeared that BMP-2 and BMP-4 as
bone morphogens were stimulating an osteoblastic-differ-
entiation program in vascular cells directed by the osteoblast-
specific transcription factors. These data are in agreement
with those of other investigators,34 including those
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Figure 3 | Regulation of phosphorus balance in CKD. Regulation of phosphorus homeostasis is complex. In CKD, a decrease in calcitriol
production leads to a decrease in calcium absorption, hypocalcemia, and hyperparathyroidism. Hyperparathyroidism is one factor
contributing to the decrease in the fraction of filtered phosphorus reabsorbed (decrease in the tubular reabsorption of phosphorus (TRP)).
Additionally, high levels of FGF23 and hyperphosphatemia itself contribute to reducing the TRP. However, when kidney failure becomes too
severe, hyperphosphatemia ensues.
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Figure 4 | Vascular calcification causes cardiac morbidity
and mortality in CKD. Vascular calcification increases arterial
stiffness, leading to an increase in pulse wave velocity and
pulse pressure both of which contribute to development of
cardiac ischemia, and left ventricular hypertrophy and cardiac
failure.
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who reported increased levels of BMP-2 and BMP-4 in
atherosclerotic lesions.35,36 However, the primary human
VSMC cultures did not mineralize the extracellular matrix as
osteoblast cultures do (Figure 6).37 When media phosphorus
was increased by 1 or 2 mM to 2 or 3 mM (equal to a serum
phosphorus of 6–9 mg per 100 ml), heavy matrix mineraliza-
tion ensued. Analysis of the osteoblastic transcription
program revealed that the very low levels of osterix
expression in the starting cultures were increased several
fold by the increase in media phosphorus. Blocking the
increase in osterix expression in high-phosphate media
prevented matrix mineralization.38 Both our translational
model in vivo and our cell culture model in vivo represent
mineralization due to the atherosclerotic process. We observe
mainly neointimal calcification in vivo, and the medial
calcification we observe is in proximity to atherosclerotic
plaques.
When we examined aortas from our various groups of
high-fat-fed LDLR/ animals, we found that the sham-
operated, high-fat-fed animals had low or undetectable levels
of osterix expression that were increased several fold when
CKD was induced.38 Most importantly, treatment of CKD
high-fat-fed hyperphosphatemic animals with phosphate
binders inhibited osterix expression (Figure 7).38 As expected
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Figure 5 | Control of hyperphosphatemia in translational studies results in reduction of established vascular calcium levels.
LDLR/ mice on high-fat diets with CKD have established vascular calcification at 22 weeks (baseline), which increases in vehicle-treated
animals killed at 28 weeks (veh). However, in animals treated with sevelamer carbonate (1 and 3% sev), aortic calcium levels were
significantly reduced compared with baseline, as the hyperphosphatemia was controlled.28
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Figure 6 | Schematic representation of the experimental scheme for in vitro studies demonstrating that high phosphorus level
causes vascular calcification and osteoblastic gene expression. Human VSMCs derived from atherosclerotic aortas expressed increased
levels of morphogens, specific transcription factors, and biomarkers of the osteoblast, and decreased levels of those corresponding to
contractile human VSMCs. Yet the cells did not mineralize until media Pi was increased from 1 to 2 mM. High level of Pi in the media
stimulated osterix expression, and when osterix expression was diminished in the presence of high media Pi level, there was no
mineralization.38
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without a critical osteoblastic transcription factor, matrix
mineralization (neointimal calcification) was severely com-
promised similar to results shown in Figure 5.
The mechanism of phosphorus stimulation of matrix
mineralization in vitro has been studied by Jono et al.39 and
Li et al.40 in VSMCs and by Beck et al.41,42 in osteoblastic
cells. These authors have demonstrated that the effect of
media phosphorus was through activation of ERK1/2, and
was blocked by an inhibitor of sodium-dependent phosphate
transport proteins, phosphonoformic acid (PFA). However
the effects of PFA are relatively specific to the type-2 Na/Pi
co-transporters.43 A sodium-dependent phosphate transport
protein of the VSMCs is Pit-1, and an RNAi to Pit-1 also
inhibited the actions of high-phosphorus media.40,43 The
effects of PFA in VSMC mineralization may have been due to
the role of phosphonates to inhibit phosphate crystal
formation, although NaPi2a has recently been found in
osteoblast-like cells.43,44 Other recent studies of Pi transport
in VSMCs indicate that Pit-1 and Pit-2 account for sodium-
dependent transport, which is only modestly inhibited by
high concentrations of PFA.45 In subsequent studies reported
in abstract form at this writing, the authors demonstrate that
these concentrations of PFA induce cytotoxicity.46 Despite
the recent clarification regarding the effects of PFA on
VSMCs, the studies with RNAi to Pit-140,45 indicate that the
effects of blocking the actions of high-phosphorus culture
media in vitro are similar to those of lowering serum
phosphorus in vivo, that of inhibiting osteoblastic stimula-
tion of matrix mineralization.
Thus, phosphorus is more than a stimulator of vascular
calcification acting through an elevated calcium–phosphorus
product in CKD and ESKD. It is a signaling molecule serving
to complete osteoblastic differentiation in the aorta, and an
important component of the action of CKD to stimulate
atherosclerotic calcification. The results of the translational
animal studies and the studies in vitro just discussed are in
agreement with a new clinical consensus that has led to
renaming of renal osteodystrophy by the KDIGO Foundation
as the CKD mineral bone disorder (CKD-MBD) in recogni-
tion of the roles of the skeleton in hyperphosphatemia and
vascular calcification.47
OTHER HYPERPHOSPHATEMIC SYNDROMES
Hyperphosphatemic syndromes occur due to a variety of
causes (Table 1). Hyperphosphatemia due to intravenous
hyperalimentation (total parenteral nutrition (TPN)) in an
immobilized patient is the most common cause of hyperpho-
sphatemia in clinical medicine. Here, the phosphate content
of the TPN prescription equivalent to normal dietary intake
is associated with hyperphosphatemia, leading to removal of
phosphate from the parenteral alimentation. Sometimes
removal of phosphate intake does not correct the hyperpho-
sphatemia and patients require inhibition of bone resorption
to correct the hyperphosphatemia. The immobilization
syndrome has at least two key features in common with the
hyperphosphatemia of CKD. The first is severe inhibition of
bone formation associated with immobilization that resem-
bles inhibition of bone formation in the ABD of CKD/ESKD.
The second is excess bone resorption contributing to
hyperphosphatemia. The major difference from hyperpho-
sphatemia of CKD may be duration of the syndrome, which
in the case of immobilization is insufficient to calcify the
vasculature and produce cardiac events due to the hyperpho-
sphatemia.
Transcellular shifts of phosphate associated with catabo-
lism, tumor lysis, or rhabdomyolysis are also relatively
common causes of hyperphosphatemia (Table 1). Hyperpho-
sphatemic syndromes due to decreased renal excretion
besides CKD are uncommon in clinical medicine. Of these,
FGF23 deficiency genetically produced in the mouse is
especially instructive. FGF23-null mice exhibit hyperpho-
sphatemia, elevated calcitriol levels, and increased skeletal
mineralization, including chondrosseous junctions, the
primary spongiosa, and heterotopic sites such as various
organs and the vasculature.48 The mice die at about 13 weeks
due to cardiovascular complications. The phenotype of the
FGF23-null mice is rescued by production of a double genetic
deficiency for FGF23 and 25 hydroxycholecalciferol-1-alpha
hydroxylase.49 This demonstrates the role of excess calcitriol
in the FGF23-null phenotype. Interestingly, the vascular
calcification of this phenotype is also rescued by low-
phosphate diets.50
FGF23 is a recently discovered phosphaturic hormone
responsible for autosomal dominant hypophosphatemic
rickets through an activating mutation.51 The recent
discovery that inactivating mutations cause the rare human
disease of familial tumoral calcinosis completes the picture
presented by the FGF23-null mice due to similarities in the
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phenotypes. The premature cardiac death in FGF23-deficient
mice is reminiscent of the early coronary artery disease in
Klotho mice.52,53 Klotho has recently been discovered to
function as a co-receptor for FGF23 in the proximal tubule,54
and its inactivation has also been found to cause familial
tumoral calcinosis.55 Thus, the role of hyperphosphatemia in
stimulating heterotopic mineralization has clearly been
demonstrated in mice and humans. The unique aspect of
hyperphosphatemia in CKD is that the skeletal response to
hyperphosphatemia, increased deposition of phosphate, is
blocked.
RENAL OSTEODYSTROPHY
There are several disorders of bone remodeling that
complicate CKD and ESKD. These have been characterized
histomorphometrically and are correlated to PTH levels to
estimate bone turnover rates. This process has to be replaced
in order to monitor the skeleton more closely as is necessary
to optimize cardiovascular therapy in CKD. Our current
practice of using PTH levels to correlate with bone turnover
is insufficient in terms of sensitivity and fails to detect excess
bone resorption. Presently, high PTH levels (4500 pg ml1
with an intact hormone assay) are thought to indicate
increased skeletal remodeling due to secondary hyperpara-
thyroidism. Although this is generally correct, it does not
measure the impact of elevated remodeling in CKD on bone
mass or strength. The elevated remodeling associated with
secondary hyperparathyroidism, produces an osteoblast
phenotype that has reduced secretion of type-1 collagen
and increased production of RANK ligand, the critical
osteoclast differentiation factor. This results in bone resorp-
tion outpacing bone formation. In addition, the high
remodeling rates are characterized by insufficient replace-
ment of newly formed atypical ‘woven’ bone with bone
formed on collagen lamellae. Thus, even with normal bone
mass, skeletal frailty may be problematic in high turnover
osteodystrophy in CKD/ESKD.
A secondary effect of hyperphosphatemia in CKD is
stimulation of nodular hyperplasia of the parathyroid
glands.56–59 Hyperplastic chief cells from the nodular areas
are of clonal origin demonstrating less of cell-cycle control.60
Clinically, this phenomenon accounts for the loss of control
of the adaptive function of secondary hyperparathyroidism in
CKD, and results in highly elevated PTH levels that are
difficult to treat and clinical manifestations of severe
secondary hyperparathyroidism. This often leads to para-
thyroidectomy in order to treat the clinical complications of
the uncontrolled PTH levels.
With prevalent administration of high doses of vitamin D
analogs in CKD/ESKD, a newer (discovered in the 1980s)
low-turnover form of renal osteodystrophy has become
increasingly common, termed the ABD.61–63 The ABD was
originally thought to be due to suppression of osteoblast
function with high doses of vitamin D analogs.61,63 The
finding that vitamin D analogs stimulate, and not inhibit,
bone formation and osteoblast function has put this
contention to rest.64–66 What is likely the case is that the
negative effects of CKD on skeletal anabolism are uncovered
by suppression of PTH. This demonstrates that higher than
normal levels of PTH are required to maintain bone
remodeling in CKD.67 Many different mechanisms of
resistance to the actions of PTH in CKD have been proposed,
including desensitization of the PTH receptor by persistent
high PTH levels.68 While this is likely, another mechanism is
probably central and critical. The endosteal osteoblast forms
the niche of the hematopoietic stem cell,69–71 and loss of
osteoblast surface and number as a result of loss of skeletal
anabolism due to kidney injury threatens hematopoiesis.
There are three principles that regulate the hematopoietic
stem cell niche, the BMPs, the Wnts, and PTH.69,71 Loss of
the influence of BMP or Wnt as a result of kidney injury
would lead to a need for higher levels of PTH to protect niche
function and skeletal remodeling. The point that is well
established is that in ESKD, higher than normal levels of PTH
are required to maintain normal rates of skeletal remodeling,
that is, PTH levels recommended in the KDOQI guidelines.
The loss of skeletal remodeling after renal injury produces
a mechanism of increasing PTH secretion due to the decrease
in the exchangeable phosphorus pool size (Figure 2). Now
boluses of phosphorus, as with meals, distribute in a smaller
pool and produce intermittent short-lived stimuli to
increased PTH secretion either through secondary effects
on serum Ca or due to direct effects of transient increases in
serum phosphorus that may be within the normal range. All
this occurs in the face of normal fasting levels of Ca and PO4.
Renal osteodystrophy begins early in CKD. It is often first
detected by elevated PTH levels in the face of normal Ca, PO4
and calcitriol levels.14 In this setting, the cause of the increase
in PTH levels is a decrease in the exchangeable PO4 pool size
due to a loss of the skeletal mineralization front that occurs
when the normal stimulus to bone formation is lost due to
kidney injury. Despite recent studies, the role of FGF23,
which is increased before changes in Ca, Pi, or calcitriol, in
PTH secretion is unclear.72 The underpinning of renal
osteodystrophy by a loss of skeletal anabolic potential due
to kidney injury is poorly appreciated, but it is often
uncovered when PTH levels are suppressed to near-normal
levels, producing the ABD.62,63,73
OSTEOPOROSIS IN CKD
The balance between bone formation and resorption may be
either negative or positive in CKD. When positive, osteo-
sclerosis results, but this is rare in modern medicine. In the
case of negative bone balance, bone loss occurs in cortical and
cancellous bone, and is more rapid when bone turnover is
high. In those cases, bone densitometry will detect osteopenia
or osteoporosis. The prevalence of osteoporosis in the
population with CKD exceeds the prevalence in the general
population.74–76 Osteoporosis is observed in CKD before
dialysis is required for end-stage kidney failure.77 When bone
turnover is high, as in secondary hyperparathyroidism with
osteitis fibrosa, bone resorption rates are in excess of bone
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formation and osteopenia progressing to osteoporosis may
result. When bone turnover is low, although both bone
formation rates and bone resorption may be reduced,
resorption is in excess and loss of bone mass occurs. Thus,
osteoporosis may be observed with either the high-turn-
over77–80 or low-turnover81 forms of osteodystrophy. When
bone resorption exceeds bone formation rates in CKD,
phosphorus and calcium release contribute to hyperpho-
sphatemia and hypercalcemia. The increase in skeletal
mineral deposition that should result from hyperphosphate-
mia or hypercalcemia is blocked, and heterotopic miner-
alization is stimulated, especially in the vasculature. The
failure of the skeleton to absorb positive phosphate balance in
CKD is an important stimulus to heterotopic mineralization,
and links the skeleton and osteoporosis in CKD to
cardiovascular events and mortality. This link between
osteoporosis and vascular calcification, now partly defined
in CKD, is not specific to CKD. Type-2 osteoporosis is
strongly associated with vascular calcification, and perhaps,
the mechanisms defined in CKD related to the serum
phosphorus as a signal and positive phosphate balance also
apply.
The discussion of osteoporosis in CKD above is focused
on osteoporosis caused by CKD itself. However, many
patients with CKD have osteoporosis independent of CKD.
These patients may be elderly or may have post-menopausal
osteoporosis. In addition, it is clear that gonadal hormone
deficiency, as in post-menopausal osteoporosis, is also caused
by CKD and is another factor in the pathogenesis of
osteoporosis in CKD. Thus, osteoporosis in CKD presents a
difficult differential diagnosis between the type-2 osteoporo-
sis of aging, gonadal hormone deficiency, and excess bone
resorption associated with the CKD-MBD.
CONCLUSION
In conclusion, hyperphosphatemia in CKD is a distinct
syndrome. It represents one component of the increased risk
of cardiovascular disease in CKD that has been analyzed
successfully. Hyperphosphatemia in CKD represents a signal
that heterotopic sites of mineralization are being used to
compensate for the failure of reservoir function of the
skeleton in positive phosphate balance. In fact, hyperpho-
sphatemia itself is one of the signals activating heterotopic
deposition sites, and functions as a signaling molecule in
stimulating atherosclerotic neointimal mineralization that is
markedly increased in CKD. The unique features of
hyperphosphatemia in CKD, especially failure of the skeletal
reservoir function, qualify it as a distinct syndrome
characterized by phosphate excretion failure, contribution
of the skeleton to hyperphosphatemia, heterotopic miner-
alization, including the vasculature, and severe cardiovascular
disease leading to morbid cardiac events and often to demise.
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